Newmark arranged the sale of Burlington BioCenter, a life science facility in Burlington, MA. Although Newmark did not identify the owner-user that bought the 109,085-square-foot property, published reports said it was Northeastern University. The seller was MetLife Investment Management, which paid $103 million to acquire it in 2022.
The sale was facilitated by Newmark co-head of U.S. Capital Markets Robert Griffin, along with Boston Capital Markets executive vice chairman Edward Maher, vice chairman Matthew Pullen, executive managing director James Tribble, senior managing director Samantha Hallowell and associate firector William Sleeper. Financial analyst Grady Zink provided analytical support.
“Burlington BioCenter stands alone in the Burlington submarket for its turnkey laboratory infrastructure and modern, full-floor buildouts,” said Pullen. “In a region where many life science buildings remain in shell condition, this asset is truly differentiated by its cutting-edge systems and immediate occupancy potential.”
Originally completed in 2019 with its interior laboratory buildouts finalized in 2022, the building features high-performance laboratory infrastructure.
The post Burlington BioCenter Trades to Owner-User appeared first on Connect CRE.
